Juvenile myelomonocytic leukemia
Revision as of 07:08, 18 July 2023 by Warner-admin (talk | contribs) (Text replacement - ", <20 p" to ", fewer than 20 p")
1 regimens on this page
1 variants on this page
|
First-line therapy
Azacitidine monotherapy
Regimen
| Study | Dates of enrollment | Evidence |
|---|---|---|
| Niemeyer et al. 2021 (AZA-JMML-001) | 2015-2017 | Phase 2, fewer than 20 pts (RT) |
References
- AZA-JMML-001: Niemeyer CM, Flotho C, Lipka DB, Starý J, Rössig C, Baruchel A, Klingebiel T, Micalizzi C, Michel G, Nysom K, Rives S, Schmugge Liner M, Zecca M, Schönung M, Baumann I, Nöllke P, Benettaib B, Biserna N, Poon J, Simcock M, Patturajan M, Menezes D, Gaudy A, van den Heuvel-Eibrink MM, Locatelli F. Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial. Blood Adv. 2021 Jul 27;5(14):2901-2908. link to original article link to PMC article PubMed NCT02447666